



ASX Announcement

23 April 2026

Atomo Q3 FY26 Quarterly Investor Webinar Presentation

SYDNEY Australia, 23 April 2026 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) will release its Q3 FY26 Results on Tuesday, 28th April 2026.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Tuesday 28th April 2026 at 2:00 pm (AEST).

To access the webinar please pre-register by clicking [this link](#).

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement. This platform offers an opportunity to submit questions and share comments. To access Atomo's Investor Hub please scan the QR code or visit <https://investors.atomodiagnostics.com/auth/signup>



~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

Investor Queries
investorqueries@atomodiagnostics.com

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com